Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
IPO Year: 1991
Exchange: NASDAQ
Website: vrtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $575.00 | Buy | Citigroup |
| 10/16/2024 | Sector Perform | Scotiabank | |
| 10/10/2024 | Mkt Perform | Raymond James | |
| 8/5/2024 | $472.00 → $509.00 | Overweight → Equal Weight | Barclays |
| 6/27/2024 | $545.00 | Buy | Redburn Atlantic |
| 4/11/2024 | $438.00 | In-line → Outperform | Evercore ISI |
| 2/15/2024 | $515.00 | Outperform | Wolfe Research |
| 2/6/2024 | $436.00 → $438.00 | Outperform → In-line | Evercore ISI |
| 2/2/2024 | Outperform → Mkt Perform | Bernstein | |
| 1/31/2024 | $325.00 | Neutral → Underperform | Robert W. Baird |
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. "The third quarter marked anot
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET. Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A rep
- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinical remission -- - First proteinuria data on povetacicept in primary membranous nephropathy shows mean UPCR reduction from baseline of 62% at 24 weeks – - Global Phase 3 RAINIER trial of povetacicept in IgA nephropathy now underway – – Enrollment and dosing ongoing in Phase 3 portion of the global Phase 2/3 pivotal clinical trial of inaxaplin for the treatment of APOL1-mediated kidney disease – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today provided updates on multiple kidney dise
-- Phase 3 abstract selected for presentation in "Best Abstract" session -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — "Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy" will be presented as an oral pres
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived web
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Sept. 27, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets tha
TORONTO, Sept. 26, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor, a once-daily triple combination therapy for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. "Vanzacaftor raises the bar set by TRIKAFTA® by demonstrating comparable lung function improvement and additional improve
– Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA® in ppFEV1 and further improvement of CFTR function as measured by sweat chloride – – Real-world evidence and clinical studies of TRIKAFTA® continue to show sustained long-term benefits including improvement in pancreatic function in young patients – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor ("vanza triple") — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC). Vertex al
– First regulatory authorization of a CRISPR-based gene-editing therapy in Canada – TORONTO, Sept. 25, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced Health Canada has granted Marketing Authorization for PrCASGEVY® (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). There are an estimated 2,000 patients eligible for CASGEVY in Canada, the majority of whom are living with SCD.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 11:30 a.m. ET. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 9:10 a.m. ET. A live webcast of management's rem
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $450 to $500.
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 11.09% on an annualized basis producing an average annual return of 24.11%. Currently, Vertex Pharmaceuticals has a market capitalization of $126.33 billion. Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $293.44 today based on a price of $489.55 for VRTX at the time of writing. Vertex Pharmaceuticals's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Be
Cantor Fitzgerald analyst Olivia Brayer maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $440 to $480.
HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $462 to $500.
- Three-year extension of collaboration to use genomics to accelerate drug discovery - - The range of therapeutic areas and genomic data insights will be expanded and the companies will also explore using genomic risk to better define patient subgroups -
- Reuters
- Reuters
-Approximately 200 people with certain rare CF mutations are now eligible for TRIKAFTA®-TORONTO, July 15, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical and/or in vitro data. TRIKAFTA® was previously approved by Health Canada for use in people with CF aged 2 years and older with at least one F508del mutation and is now ap
In the preceding three months, 13 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), presenting a wide array of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 4 4 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 1 0 0 2M Ago 0 1 1 0 0 3M Ago 3 2 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $477.54, a high estimate o
Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and raises the price target from $402 to $455.
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. "The third quarter marked anot
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived web
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of January 30, 2025 — — Advancing broad and deep clinical pipeline with multiple milestones expected in H2:24 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the second quarter e
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived
— Product revenue of $2.69 billion, a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sciences, including povetacicept, a Phase 3-ready asset in IgA nephropathy and potential pipeline-in-a-product — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the first quarter en
- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast
— Full year product revenue of $9.87 billion, an 11% increase compared to full year 2022 — — Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion — — CASGEVYTM approved in the U.S., Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Vertex on track to submit new drug applications (NDAs) to the FDA by mid-2024 for both VX-548 in Acute Pain and the Vanzacaftor Triple in CF — — Broad and deep clinical-stage pipeline continues to advance across 10 disease areas — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2023 and provided full year 2024
– Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized controlled trials – – Treatment with VX-548 was also shown to be effective in the single arm study in a broad range of surgical and non-surgical pain conditions for up to 14 days – – VX-548 was safe and well tolerated in all three studies – – Vertex plans to submit a New Drug Application to the FDA by mid-2024 – – Vertex to host investor call January 30 at 8:00 a.m. ET – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced positive results from its Phas
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2023 financial results on Monday, February 5, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2023 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
Citigroup initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $575.00
Scotiabank initiated coverage of Vertex Pharma with a rating of Sector Perform
Raymond James resumed coverage of Vertex Pharma with a rating of Mkt Perform
Barclays downgraded Vertex Pharma from Overweight to Equal Weight and set a new price target of $509.00 from $472.00 previously
Redburn Atlantic initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $545.00
Evercore ISI upgraded Vertex Pharma from In-line to Outperform and set a new price target of $438.00
Wolfe Research initiated coverage of Vertex Pharma with a rating of Outperform and set a new price target of $515.00
Evercore ISI downgraded Vertex Pharma from Outperform to In-line and set a new price target of $438.00 from $436.00 previously
Bernstein downgraded Vertex Pharma from Outperform to Mkt Perform
Robert W. Baird downgraded Vertex Pharma from Neutral to Underperform and set a new price target of $325.00
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-2) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 217660, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug ORKAMBI (SUPPL-5) with active ingredient IVACAFTOR; LUMACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 211358, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug SYMDEKO (COPACKAGED) (SUPPL-11) with active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 210491, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug KALYDECO (SUPPL-17) with active ingredient IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 207925, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug ORKAMBI (SUPPL-17) with active ingredient IVACAFTOR; LUMACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 206038, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug KALYDECO (SUPPL-16) with active ingredient IVACAFTOR has changed to 'Approval' on 05/03/2023. Application Category: NDA, Application Number: 207925, Application Classification: Efficacy
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (ORIG-1) with active ingredient ELEXACAFTOR;TEZACAFTOR;IVACAFTOR;IVACAFTOR has changed to 'Approval' on 04/26/2023. Application Category: NDA, Application Number: 217660, Application Classification: Type 3 - New Dosage Form
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-9) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 04/26/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022. Mr. Biller will report directly to Vertex's Chief Executive Officer and President, Reshma Kewalramani, M.D., and join the company's Executive Committee. In this role, Mr. Biller will oversee all of Vertex's global legal and compliance functions. "Jonathan is an outstanding addition to Vertex with his deep legal, industry and business experience, and I am delighted to welcome him to the company," said Dr. Kewalramani. "Jonathan will lead an extraordinarily talented legal and compliance team and support our continued growth as we expand
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Stuart A. Arbuckle has been appointed as the company's Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex's Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year. "This is an exciting time for Vertex, as we continue to expand access to our cystic fibrosis portfolio around the world and prepare to bring forward new therapies with the potential to transform the treatment of multiple serious diseases," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Ver
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors